Search Results
Results found for "GPCR data platform"
- Immunomodulatory Role of Neuropeptides in the Cornea
Read more at the source #DrGPCR #GPCR #IndustryNews
- Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Microbial Metabolites Orchestrate a Distinct Multi-Tiered Regulatory Network in the Intestinal Epith
Read more at the source #DrGPCR #GPCR #IndustryNews
- Sosei Heptares recently hosted their annual Scientific Advisory Board (SAB)
Read more at the source #DrGPCR #GPCR #IndustryNews
- Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares
Read more at the source #DrGPCR #GPCR #IndustryNews
- Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies
Read more at the source #DrGPCR #GPCR #IndustryNews
- Jan Steyaert Named 2022 Jacob and Louise Gabbay Award Winner
Read more at the source #DrGPCR #GPCR #IndustryNews
- Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI
Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex Raises $10 Million In Equity Financing
Unregistered Warrants have an exercise price of $6.50 per ADS, will become exercisable in 60 days after their date of issuance and will expire six years from their date of issuance. Read more at the source #DrGPCR #GPCR #IndustryNews
- X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
Read more at the source #DrGPCR #GPCR #IndustryNews
- Targeting the M1 muscarinic receptor in neurodegenerative disease
Translational Sciences Associate Director at Sosei Heptares, recently presented at the Keystone Symposia GPCR Read more at the source #DrGPCR #GPCR #IndustryNews
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
compounds for Charcot-Marie-Tooth type 1A neuropathy (CMT1A) and pain. " Read more at the source #DrGPCR #GPCR
- Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Regulation of rod photoreceptor function by farnesylated G-protein γ-subunits
Read more at the source #DrGPCR #GPCR #IndustryNews
- Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ...
Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR1 Read more at the source #DrGPCR #GPCR #IndustryNews
- Domain Therapeutics Raises $42m Series A Financing
specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs Read more at the source #DrGPCR #GPCR #IndustryNews
- Platelets in the NETworks interweaving inflammation and thrombosis
Read more at the source #DrGPCR #GPCR #IndustryNews
- β2-Adrenergic Receptor Expression and Intracellular Signaling in B Cells Are Highly Dynamic during..
Read more at the source #DrGPCR #GPCR #IndustryNews
- Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of ...
$5 Million Pre-series A Round to Accelerate Commercialization of Ultrahigh Throughput Drug Discovery Platform The proceeds will be used to further build the company’s discovery platform and operations. Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like These molecules are then evaluated at unprecedented speed and scale on hundreds of GPCR targets simultaneously Read more at the source #DrGPCR #GPCR #IndustryNews
- Effects of Small Molecule Ligands on ACKR3 Receptors
Read more at the source #DrGPCR #GPCR #IndustryNews
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
Changes to Drive the Company Through the Next Stage of its Evolution "New team focused on expanding its GPCR-focused structure-based drug design platform and enhancing translational medicine capabilities • ‘Venture-like Read more at the source #DrGPCR #GPCR #IndustryNews
- Third Rock pushes newest fund over $1B line as it marks 15 years in venture capital
Read more at the source #DrGPCR #GPCR #IndustryNews
- Michel Bouvier appointed Knight of the Ordre national du Québec
Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Presents Clinical And Research Results At ENDO 2022
Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex raises $4.2 million in equity financing
Unregistered Warrants have an exercise price of $1.90 per ADS, will become exercisable in 60 days after their date of issuance and will expire five years from their date of issuance. " Read more at the source #DrGPCR #GPCR #IndustryNews
- ShouTi Pharma CEO Dr. Raymond Stevens was interviewed by Moira Gunn of the NPR TechNation podcast
April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
Series of Potent and Selective Compounds Identified Using Proprietary Allosteric Modulator Screening Platform Read more at the source #DrGPCR #GPCR #IndustryNews
- Trevena Announce Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu ...
Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical "Submission supported by data Read more at the source #DrGPCR #GPCR #IndustryNews
